Pfiz­er's JAK1 chal­lenger to Dupix­ent shines in an­oth­er PhI­II, but safe­ty is­sues still cast a shad­ow

Pfiz­er is rack­ing up am­mu­ni­tion for its full-on as­sault against Re­gen­eron and Sanofi’s Dupix­ent fran­chise, with the lat­est topline win for an oral atopic der­mati­tis drug that it’s steer­ing to the FDA lat­er this year. But the new da­ta cut is do­ing lit­tle to ease safe­ty con­cerns.

JADE COM­PARE is the third Phase III tri­al in the abroc­i­tinib eczema pro­gram. Un­like JADE MONO-1 and JADE MONO-2, which en­rolled pa­tients who ei­ther don’t re­spond well or can’t tol­er­ate top­i­cal treat­ment, this new tri­al ze­roed in on those al­so tak­ing top­i­cal ther­a­pies on back­ground.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.